The first wave of genetically targeted therapies for cancer focused on drugging gene
products that are recurrently mutated in specific cancer types. However, mutational analysis …

The rapid evolution of treatment for advanced lung cancer is a story of how scientists have
struggled to move from nonselective cytotoxic chemotherapy to personalized precision …

Background Among patients with non–small-cell lung cancer (NSCLC), MET exon 14
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …

Background The tumor microenvironment (TME) is a critical player in tumor progression,
metastasis and therapy outcomes. Tumor-associated macrophages (TAMs) are a well …

PURPOSE Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with
cytotoxic chemotherapy is highly effective for the treatment of advanced non–small-cell lung …

Introduction Limited clinical data are available regarding the efficacy of EGFR tyrosine
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …

Osimertinib is the only EGFR-tyrosine kinase inhibitor (TKI) capable of overcoming EGFR-
T790M–mutated NSCLC, but osimertinib-resistant EGFR triple mutations …

Objectives ICIs have been approved and are routinely administered regardless of
performance status (PS), despite randomized clinical trials of ICIs alone or combined with …

The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …

Background Acquired epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)
resistance limits the long-term clinical efficacy of tyrosine kinase-targeting drugs. Although …